These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 9079825

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
    Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA.
    Cancer Res; 1993 Jul 15; 53(14):3257-61. PubMed ID: 7686815
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H.
    Br J Cancer; 2001 Apr 20; 84(8):1052-7. PubMed ID: 11308253
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.
    Lipford GB, Hoffman M, Wagner H, Heeg K.
    J Immunol; 1993 Feb 15; 150(4):1212-22. PubMed ID: 7679422
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
    De Bruijn ML, Schumacher TN, Nieland JD, Ploegh HL, Kast WM, Melief CJ.
    Eur J Immunol; 1991 Dec 15; 21(12):2963-70. PubMed ID: 1660811
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, DeLeo AB.
    Clin Cancer Res; 2000 Mar 15; 6(3):979-86. PubMed ID: 10741724
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
    Tremblay N, Fontaine P, Perreault C.
    Transplantation; 1994 Jul 15; 58(1):59-67. PubMed ID: 8036709
    [Abstract] [Full Text] [Related]

  • 17. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells.
    Lacabanne V, Viguier M, Guillet JG, Choppin J.
    Eur J Immunol; 1996 Nov 15; 26(11):2635-9. PubMed ID: 8921949
    [Abstract] [Full Text] [Related]

  • 18. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ, Chan HW, Karbach J, Salter RD, Knuth A, Lotze MT, Storkus WJ.
    Eur J Immunol; 1996 Nov 15; 26(11):2613-23. PubMed ID: 8921947
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
    Yu Z, Liu X, McCarty TM, Diamond DJ, Ellenhorn JD.
    J Surg Res; 1997 May 15; 69(2):337-43. PubMed ID: 9224403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.